Teva has announced a change at the top of its research and development organization, with an important distinction between leaving an executive role and finishing the handover. Dr. Eric Hughes is stepping down immediately from his positions but will continue helping with the transition over the coming months. The company’s announcement was released on November 18 in the United States, at midnight as November 19 began in Israel.
In its SEC report, Teva said Hughes notified the company of his intention to resign on November 17. The public announcement said he had accepted an opportunity outside Teva. His next employer was not identified.
Who Takes Responsibility Now
David Gardiner, head of Innovative Medicines and Clinical Development, will immediately lead the transition, reporting to chief executive Richard Francis. Teva said the search for a permanent successor would begin immediately.
That does not make Gardiner the confirmed permanent replacement. Nor does Hughes’s continuing assistance mean he retains his former executive responsibilities: the filing distinguishes the immediate role exit from the following months of transition work.
A Revenue Ambition Remains a Forecast
Teva said its strategy, priorities and business expectations were unchanged. It reiterated the ambition presented at its November 11 R&D day to generate $6 billion to $7 billion in innovative medicines revenue in 2030.
That is a future management target, rather than revenue already earned or a guaranteed outcome. The leadership announcement provides no basis for attributing the departure to the failure of a particular trial or a change in a development program.
What Has Yet to Be Announced
Teva has not named a permanent successor or supplied an exact date for the handover to end. Those details will help establish the longer term leadership structure. For now, the new information concerns the reassignment of management responsibility and the transition arrangement, alongside the company’s stated intention to maintain its plans.